175 results
Page 3 of 9
424B3
oo5g0w
19 Jan 22
Prospectus supplement
4:05pm
8-K
vgo0ft1
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
8nzi 5aem0w
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
zcdic3uomhu6hwwn 2ag
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.2
d75jqv0
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
v91ajqrijwryh
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
qm8r1p6u3o
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
l4yiaa
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
vdkr39j4h jze5yp
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
qku1016zp65zzld vrtx
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
zi7k60
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
v2n33zdu6t2lm5w0368o
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-10.1
0bmgz4v76762k071zyk
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
ac2rp5cqs1lm1m2
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.1
qhd1u
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
k1xlhr1g0ij 3p
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am